Accurius Therapeutics Inc mission is to fundamentally transform cancer treatment and improve outcomes for cancer patients by developing a first-of-a-kind inhalable agent that is designed to be a safe and effective treatment for mNSCLC and other cancers metastatic to the lung. Firm have designed an engineered oncolytic virus based on the Influenza A virus (eIAV) that selectively infects and destroys cancer cells while sparing healthy cells and activates the bodys own anti-tumor immune response. There are more than 230,000 new cases of lung cancer and over 130,000 deaths due to lung cancer each year in the U.S. Approximately 120,000 people each year will present with metastatic Non-Small Cell Lung Cancer (mNSCLC) for the first time, and only 7% of these patients will survive five years or more. We think the treatment futility surrounding this disease is unacceptable and were focused on changing it. This treatment is expected to improve overall survival rates for the metastatic NSCLC patient population as well for the 50,000 patients each year with different tumor types that have their cancer metastasize to the lung.
